Patents by Inventor Stephanie Moya

Stephanie Moya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using thrombin derivatives to treat medulloblastoma
    Patent number: 10220078
    Abstract: Provided herein are methods for using a thrombin peptide derivative to treat a medulloblastoma. In one embodiment, the method includes administering to a subject having a medulloblastoma an effective amount of a thrombin peptide derivative, and exposing cells of the medulloblastoma of the subject to a cancer treatment after administering the thrombin peptide derivative to the subject. An example of a cancer treatment is radiation therapy. In one embodiment, viability of cells of the medulloblastoma is decreased compared to viability of cells of the medulloblastoma before the administering and the exposing. The cells of the medulloblastoma having decreased viability can be cancer stem cells. In one embodiment, shrinkage of the medulloblastoma in the subject is increased compared to shrinkage of the medulloblastoma before the administering and the exposing.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: March 5, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Darrell Carney, Carla Kantara, Stephanie Moya
  • METHODS OF USING THROMBIN DERIVATIVES TO TREAT MEDULLOBLASTOMA
    Publication number: 20150359855
    Abstract: Provided herein are methods for using a thrombin peptide derivative to treat a medulloblastoma. In one embodiment, the method includes administering to a subject having a medulloblastoma an effective amount of a thrombin peptide derivative, and exposing cells of the medulloblastoma of the subject to a cancer treatment after administering the thrombin peptide derivative to the subject. An example of a cancer treatment is radiation therapy. In one embodiment, viability of cells of the medulloblastoma is decreased compared to viability of cells of the medulloblastoma before the administering and the exposing. The cells of the medulloblastoma having decreased viability can be cancer stem cells. In one embodiment, shrinkage of the medulloblastoma in the subject is increased compared to shrinkage of the medulloblastoma before the administering and the exposing.
    Type: Application
    Filed: June 11, 2015
    Publication date: December 17, 2015
    Inventors: Darrell Carney, Carla Kantara, Stephanie Moya